Cargando…
Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether...
Autores principales: | Bazydlo-Guzenda, Katarzyna, Buda, Pawel, Mach, Mateusz, Pieczykolan, Jerzy, Kozlowska, Izabela, Janiszewski, Michal, Drzazga, Ewa, Dominowski, Jakub, Ziolkowski, Hubert, Wieczorek, Maciej, Gad, Shayne Cox |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459971/ https://www.ncbi.nlm.nih.gov/pubmed/34555055 http://dx.doi.org/10.1371/journal.pone.0257477 |
Ejemplares similares
-
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
por: Gunerka, Paweł, et al.
Publicado: (2020) -
Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice
por: Nakamoto, Kazuo, et al.
Publicado: (2017) -
EPA Prevents the Development of Abdominal Aortic Aneurysms through Gpr-120/Ffar-4
por: Kamata, Ryo, et al.
Publicado: (2016) -
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
por: Lückmann, Michael, et al.
Publicado: (2019) -
CPL2 and CPL3 act redundantly in FLC activation and flowering time regulation in Arabidopsis
por: Zhang, Yu, et al.
Publicado: (2022)